295 results about "Mammary Cancers" patented technology

PCT No. PCT/JP93/01737 Sec. 371 Date Apr. 29, 1996 Sec. 102(e) Date Apr. 29, 1996 PCT Filed Nov. 29, 1993 PCT Pub. No. WO94/13209 PCT Pub. Date Jun. 23, 1994A diagnostic patch comprising at least an adsorption carrier adsorbing a substance secreted from a living body, which is useful particularly for the diagnosis of mammary cancer or atopic dermatitis, and a method for the diagnosis of mammary cancer or atopic dermatitis with said preparation.

A combination hormone and melatonin therapy is provided to reduce the risk of developing, or to reduce the severity of, breast cancer by administering at least one estrogen hormone and optionally at least one progesterone-receptor-binding compound or composition and melatonin together, preferably at normal bed time.

The invention belongs to the field of pharmaceutical agents, relates to a polymer micelle lyophilized agent encapsulating an insoluble antitumor drug as well as a preparation method and an application thereof. The polymer micelle lyophilized agent is prepared by carrying out molecular self-assembly on a methoxy poly(ethylene glycol) 2000-polyester block copolymer to form micelles, and then encapsulating the insoluble antitumor drug in a hydrophobic core formed by the polyester. The lyophilized agent has high encapsulation rate, high drug loading and small particle size, can significantly improve the water solubility of the insoluble drug and result in passive targeting of more antitumor drugs to concentrate in the tumor tissues, thus improving an anti-tumor treatment effect and reducing the toxic and side effects of drugs, and can be used to prepare the drugs used for the treatment of lung cancer, intestinal cancer, mammary cancer, ovarian cancer, etc. The lyophilized agent can also be quickly dissolved and dispersed to form a transparent micellar solution after water for injection, normal saline solution and the like are added, and is used for the preparation of the drugs for treating primary intestinal cell carcinoma.

The invention relates to a DNA-targeted o-dicyano-acenaphtho pyrazine compound in the field of application of antineoplastic medicaments. The compound is prepared by taking acenaphthene quinone as a raw material and performing bromination, cyclization and aromatic nucleophilic substitution reaction. The compound is characterized in that: one end takes an amino straight chain of a flexible side chain or an annular group as an electron-donating group, while the other end takes two cyanogen groups as electron-withdrawing groups; the two ends form an electron deficient large-plane conjugated system; and the structure accords with an ideal DNA intercalator. The compound shows obvious inhibitory activity to an in vitro test of MCF-7 (human mammary cancer cells).

The invention discloses a targeted polypeptide capable of being specifically combined with tumors, particularly a targeted peptide capable of being specifically combined with liver cancer tissues and application thereof in diagnosis and treatment of liver cancer. The liver cancer targeted peptide is preferably HCC-47 of which the amino acid sequence is SQDIRTWNGTRS; and the liver cancer targeted peptide is specifically combined with the liver cancer tissues, and can not be specifically combined with cervical carcinoma cells Hela, mammary cancer cells MDA-MB231, kidney cancer cells CRL-1932 and lung cancer cells A549. The polypeptide is obtained by in-vitro biological elutriation by combining a bacteriophage display library and a living body cross sectioning technique. The polypeptide can be used in a molecular imaging preparation for early diagnosis of liver cancer. The polypeptide can also be used in targeted modification and preparation of drugs for treating liver cancer. The polypeptide can also be used for targeted modification on drug transport carriers, thereby providing a new way for diagnosing or treating patients with liver cancer.

The invention relates to a tumor targeted polypeptide, and a preparation method and application thereof. The polypeptide is disclosed as the following general formula: X1X2X3X4X5WX6X7. The invention also relates to a nucleotide sequence for coding the polypeptide, an expression vector for expressing the polypeptide and a host cell. The invention also relates to a bivalent, multivalent or polypeptide coupling substance formed by the polypeptide, a pharmaceutical composition formed by the polypeptide used as a targeted polypeptide and a preparation/development preparation capable of killing cancer cells, and application thereof. The polypeptide is the most ideal tumor targeted polypeptide at present, has important application value in tumor molecular diagnosis and targeted therapy, provides important theoretical and practical basis for early diagnosis, targeted therapy and the like of mammary cancers, lung cancers and many other tumors, and thus, has wide application prospects.

The present invention is one kind of reagent for quick immune histohcemical detection of lymphatic metastasis of mammary cancer and corresponding detecting method. Several kinds of directly marked antibody capable of distinguishing metastatic cancer cell and inherent lymph node cell are mixed into reagent and one-step reacted to stain the metastatic cancer cell in lymph node specifically. The present invention is used in the fast pathological diagnosis of early lymphatic metastasis of mammary cancer, and has raised sensitivity, high accuracy and high specificity.

The invention discloses a mutant gene group for mammary cancer risk assessment and a detection kit thereof. The mutant gene group is a mutant gene set comprising the following seven genes: BRCA1 gene, BRCA2 gene, TP53 gene, MLH1 gene, MLH3 gene, MSH3 gene and CDH1 gene. The mutant gene group of the seven genes totally carries 25 mutant sites disclosed as Table 3. The invention also discloses a detection kit of the mutant gene group for mammary cancer risk assessment, which comprises probes or primers for detecting the mutant genes in the mutant gene group. The detection kit disclosed by the invention has the advantages of high detection efficiency, high detection speed, high detectable rate and the like.

Provided is a remedy for cancer which remedy is specific to cancer tissue and has therapeutic effects on mammary cancer. The remedy is available by associating an antitumor substance with a human monoclonal antibody having amino acid sequences of SEQ. ID. NOS. 1, 2 and 3 of Sequence Listing in hypervariable regions of a heavy chain and amino acid sequences of SEQ. ID. NOS. 4, 5 and 6 of Sequence Listing in hypervariable regions of a light chain by attaching the antibody to a liposome having the antitumor substance encapsulated therein.

The present invention relates to a Her-2 immuno-histochemical diagnostic kit of mammary cancer. In its content the non-specific protein blocking agent, raat antihuman initial antibody, sheep antirat monoclonal connection antibody, enzyme-labeled PAMAM reagent and color-developing reagent prepared by using chromographorous oxidation reaction agent, developing colour agent and colour-developing buffer solution. Said invention utilizs the biological characteristics of PAMAM dendritic multimer to label antibody to implement Her-2 immuno-histochemical diagnosis of mammary cancer. Said invented kit can provide accurate, stable and effective diagnosis for mammary cancer and early tumor.

The present invention discloses a kind of micronized letrozole and its composite. Said invention utilizes a micronization process to micronize said letrozole and make the micronized letrozole be combined with a proper carrier so as to obtain a micronized letrozol preparation with proper dissolubility. Said preparation can be used for effectively curing mammary cancer.

The computer aided method of predicting mammary cancer risk includes the following steps: partitioning the mammary gland tissue area in X-ray image regularly into small areas and calculating the density characteristic value of the small areas; selecting the initial suspicious small areas with the preset density characteristic value for further research; judging the final suspicious small areas based on the information in the corresponding areas and the adjacent areas on two frames of images; and judging the near term mammary cancer risk of the testee based on the existence of the marked final suspicious small areas and predicting the mammary cancer position in case of existing final suspicious small areas. The present invention has high objectivity, high accuracy and high effectiveness in predicting mammary cancer risk.

The present invention provides a detecting instrument for early mammary cancer, skin cancer or other solid cancers. A temperature sensor of the detecting instrument is provided with at least one row of scanning probes which are uniformly arranged on a probe supporter through a comb shape. The temperature measuring range of temperature sensor is 0-45 DEG C. The head part of each scanning probe penetrates out of the probe supporter. A data transmission wire connected with tail part of each scanning probe is connected with a detecting host machine. The detecting host machine comprises the following components: a casing, a regulated power supply circuit, a data selecting switch module, keystrokes, a singlechip, a preamplifying module, an A/D converting module, a display and an alarm. The invention settles the technical problems of complicated detecting operation, high detecting expense and large detecting radiation in detecting operation of mammary cancer, skin cancer and other solid cancers. The detecting instrument can effectively eliminate various interferences in detection and has the advantages of reliable data, good repeatability, convenient use, quick detection, small volume, high automatization degree. The detecting instrument is a self-detecting device which is suitable for family and personal use for detecting early mammary cancer and other diseases.

The present invention relates to an injection vinorebin powder injection preparation and its preparation method. It is made up by using vinorebin as main medicine or adding at least one of dextran, mannitol and sorbitol as filling agent, using at least one of solvents of water for injection, acetone and ethyl alcohol to dissolve them to obtain solution, then decolouring with active carbon, filtering by using microporous filtering film, then dehydration drying by using freeze-drying or reduced pressure drying to obtain the invented powder injection for curing the diseases of non-small cell lung cancer, mammary cancer, oophoroma and lymphoma, etc.

The invention discloses three gene groups for transferring and typing prognostic numerator to breast cancer, a gene chip, an unsupervised clustering map from a gene expression profile and a method for transferring and typing prognostic numerator to breast cancer patients. The invention is characterized in that: the gene chip is point-sampled and prepared by specific cDNA or oligonucleotide of the gene groups with an lattice form on the surface of the supports, and is used for transferring and typing prognostic numerator to breast cancer; the cDNA or amplified products of primary cancer tissue specimens based on breast cancer patients are fluorescence-marked and then crossbred with the gene chip for transferring and typing prognostic numerator to breast cancer, and then the gene expression profile is obtained, and the unsupervised clustering map for transferring and typing prognostic numerator to patients comes from the gene expression profile; the method makes use of the gene chip and the gene expression profile for transferring and typing prognostic numerator to breast cancer.

The invention relates to a polypeptide with tumor-targeting performance and a preparation method. The structure of the aminophenol sequence of the polypeptide is CASPSGALRSC or CFPVPGHDLVC or CFSVPGHDIVC or CTPMSLSLSEC or CYTYPLGWHIC. The pC89 phage peptide library expressing protein polypeptides with different sequences of 10⁸ and human breast cancer cell lines MDA-MB-231 are repetitively cocultured for a few times; filtration can penetrate cell membrane to enter into the phages expressing specific polypeptide in cytolymph and / or karyon, and phages are amplified in vitro in order to carry out DNA sequencing and deduce an exogenous amino acid sequence inserted in the phages; the filtered specific polypeptide phages, other human tumor cells and normal cells are cocultured in vitro, and the tumor cell specificity of the polypeptide phages is tested; according to the testing results of polypeptide sequence and cell specificity, the polypeptide with tumor targeting is artifically synthesized. The invention as a specificity carrier of the mammary cancer-targeting genetic therapy has potential clinic application value. The invention also provides a strong technical support for the filtration of affinity specificity polypeptide of other types of malignant tumor cell strains. Moreover, the polypeptide only contains nine to eleven amino acid residues, so the polypeptide can be easily synthesized, the change of spacial position is relatively less, the quality control of the polypeptide is easy, and use is convenient.

The invention relates to a medicament-tumor number 1 capable of killing cancer cells and curing various tumors and cancers and leukemia. The medicament comprises glossy ganoderma, ginseng, herba epimedii, astragalus membranaceus, giant knotweed rhizome, Chinese caterpillar fungus, heartleaf houttuynia herb and liquorice root. The medicament capable of killing cancer cells and curing various tumors and cancers and leukemia is prepared by pure traditional Chinese medicine, is good in treatment effects, less in side effects, short in treatment course and the like, is rapid in effect and high in cure rate, has effects of killing cancer cells and improving human body immunity, has functions of prolonging life and anti-aging and is capable of curing leukemia and various tumors and cancers, such as leukemia, bone cancer, lymphoma, intestinal cancer, liver cancer, renal carcinoma, gastric cancer, pelvic cancer, uterine cancer, cervical cancer, bladder cancer, prostatic cancer, pancreatic cancer, lung cancer, brain cancer, neuroendocrine tumor, mammary cancer and esophageal cancer.

A freeze-dried powder of honokiol liposome for preparing the medicines to treat lung cancer and mammary cancer is proportionally prepared from honokiol, polyethanediol-phosphatidylethanolamine, lecithin and cholesterol. It has high synergistic and sensitizing action when it is applied in conjunction with chemicotherapeutic medicine.

The invention relates to a new application of furanodiene in pharmacy field, in particular to the application of the furanodiene in the preparation of medicines for treating the various malignant tumor diseases such as oophoroma, cervical carcinoma, gastric cancer, liver cancer, leucocythemia, lung cancer, oral carcinoma (epidermoid carcinoma), rectal adenocarcinoma, mammary cancer, malignant melanoma, colonic adenocarcinoma, nasopharyngeal carcinoma, carcinoma of prostate, etc. The invention also relates to the application of the furanodiene in the preparation of drugs for treating the diseases caused by herpesvirus, influenza virus and hepatitis B virus.

The invention discloses an oral administration pharmaceutical composition for treating mammary cancer, wherein the active constituents include the following raw material herbs (by weight portion): Chinese angelica root 20g, Sichuan fritillary bulb 15g, dried rehmannia root 10g, seeds of Job's tears 10g, ganoderma lucidum 10g, radix paeoniae rubrathe 10g, zedoary 10g, cyperus tuber 8g, pangolin scales 10g, bulb of edible tulip 10g, seed of cowherb 10g, Ligusticum wallichii 6g, achyranthes and cyathula root 6g, root of ballon flower 6g, curcuma root 10g and safflower 8g. The preparing process of the composition consists of immersing the constituents in water for 2 hours, boiling for 30 minutes, removing the medicinal soup, watering and boiling for 30 minutes, removing the medicinal soup, mixing the two medicinal soups, removing water through distilling with small fire.

The present invention relates to an application of chlorogenic acid in preparation of medicine for curing female cancers, such as mammary cancer, oophoroma and carcinoma of uterus. Said medicine is made up by using chlorogenic acid as basic effective component and pharmaceutically-acceptable auxiliary component through a certain preparation process.

The invention discloses an establishing method of a primary generation humanized mammary cancer transplantation tumor model based on Chinese population. The method comprises the following steps: (1) acquiring a human mammary cancer tissue sample; (2) performing inoculation for the first time; (3) culturing a mouse of the first inoculation; (4) performing inoculation for the second time; (5) culturing a mouse of the second inoculation; (6) performing inoculation for the third time; and (7) culturing a mouse of the third inoculation. The invention also discloses the primary generation humanized mammary cancer transplantation tumor model based on the Chinese population, which is obtained by the method. The primary generation humanized mammary cancer transplantation tumor model based on the Chinese population can be used for screening anti-mammary cancer medicaments and used as a test animal in a pharmacodynamics research. The primary generation humanized mammary cancer transplantation tumor model disclosed by the invention overcomes the problem that the existing transplantation tumor model in the Chinese population cannot truly reflect biological characteristics of the mammary cancer in a human body. Moreover, compared with the establishment of a foreign primary generation humanized mammary cancer related model, the primary generation humanized mammary cancer transplantation tumor model disclosed by the invention is used for realizing long-term and stable stimulation on the growth of primary generation humanized mammary cancer transplantation tumor and improving the method for establishing the model.

A traditional Chinese medicine for curing adverse reaction from chemotherapy after breast cancer surgery belongs to a traditional Chinese medicine for curing breast cancer. The components contain: 20g of tangshen, 20g of largehead atractylodes rhizome, 30g of radix astragali, 30g of spatholobus stem, 6g of dried orange peel, 6g of tuber pinellia, 15g of tuckahoe, 15g of scurfpea fruit, 15g of herba epimedii, 10g of radix glycyrrhizae preparata, 10g of amomum villosum, 10g of colla corii asini, 12g of dogwood, 12g of fructus ligustri lucidi and 12g of medlar. The substances in the prescription are made from natural traditional Chinese medicine plus traditional preparing methods. The materials are easy to collect, the prescription and the preparation methods are simple, and the cost of medicine preparation is low. The compatibility of the traditional Chinese medicine is simple; the medicine used in the prescription is fully natural herbal medicine, which is easy to collect and use; the preparation method is simple; the effects for taking and curing are good; the cost of the medicine is low, and the medicine is in particular suitable for the people living in remote villages far from towns; the cost is low for curing the people suffering from adverse reaction disease from chemotherapy after breast cancer surgery, which solves the problem that the local area lacks medical conditions to cure the disease because of low household income and poor living condition.

The present invention relates to an SVM mammary gland classification method based on Gaussian kernel parameter selection. The method comprises: extracting a mammary gland molybdenum target and B ultrasonic image features from a known case, and performing benign and malignant and clinical stage mark of each case data which completes the feature extraction according to the known clinical diagnosis result; performing multi-feature fusion of the molybdenum target image features and the B ultrasonic image features of the same patient's mammary gland through adoption of the cascade mode, and obtaining the feature vector of mammary gland samples; and allowing the Gaussian kernel parameter selection method to be used for the training process and the identification process of the dichotomy balance decision tree SVM multi-classification algorithm based on the Gaussian kernel. The accuracy and the efficiency of the breast cancer diagnosis can be improved.

The invention belongs to the field of Chinese medicines, in particular to a Chinese medicinal composition for treating deficiency of qi and the blood after mammary cancer surgery. The Chinese medicinal composition mainly comprises the following Chinese medicinal components by weight: 20-30g of astragalus, 9-15g of Chinese angelica, 9-15g of prepared rehmannia rhizome, 9-15g of south dodder seed, 9-15g of desertliving cistanche, 9-15g of Chinese yam, 15-20g of indian buead, 15-20g of dried large-head atractylodes rhizome, 6-10g of Chinese thorowax root, 6-10g of dried orange peel and 3-6g of liquoric root. The Chinese medicinal composition has the effects of replenishing qi to invigorate the spleen, warming the yang and tonifying the kidney, and has a definite curative effect on a patient suffering from deficiency of qi and the blood after mammary cancer surgery.

The invention discloses a mammary-cancer-susceptible-gene detection chip which comprises a solid support and a gene detection probe fixed onto the solid support. The gene detection probe comprises 31 SNP (single-nucleotide polymorphism) loci of 24 mammary-cancer-susceptible genes. The 24 mammary-cancer-susceptible genes are respectively CHEK2, PALB2, ZNF350, ESR1, C6orf97, USP7, MRPS30, AURKA, ATM, CASC16, TOX3, DNMT1, ZMIZ1, TGFB1, FGFR2, ZNF365, SLC4A7, TNRC9, TNP1, HER2, BRCA2, CCDC170, BRCA1 and CYP11A1. The gene detection probe comprises the 31 SNP loci of the 24 mammary-cancer-susceptible genes. The documents prove that the loci have higher practicality, can be used for large-scale screening of early diagnosis of diseases, have the advantages of high detection success rate, favorable technique reproducibility and high cost performance, and provide important references for diagnosis, typing and prognosis of mammary cancer, thereby implementing early diagnosis of diseases.